---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-26-000049"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2026-05-13T20:16:30+00:00"
generated_at: "2026-05-13T21:55:51.790132+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Praxis reports Q1 net loss of $92.6M; FDA accepts NDAs for ulixacaltamide and relutrigine

## Summary
- FDA accepted NDA for ulixacaltamide (Essential Tremor) with PDUFA Jan 29, 2027; relutrigine NDA (SCN2A/SCN8A DEEs) granted priority review with PDUFA Sept 27, 2026.
- Cash and investments $1.4B as of Mar 31, 2026, up from $926.1M Dec 2025; funded into 2028.
- Net loss $92.6M vs $69.3M in Q1 2025; R&D expenses $78.0M (up $17.2M YoY); G&A $27.9M (up $14.0M YoY).
- EMBRAVE Part A: elsunersen showed 77% placebo-adjusted seizure reduction; 71% patients achieved >50% reduction.
- Topline POWER1 (vormatrigine in FOS) expected Q2 2026; EMERALD (relutrigine in broad DEEs) topline Q4 2026.

## SEC filing metadata
- accession: 0001689548-26-000049
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2026-05-13T20:16:30+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/0001689548-26-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/prax-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-26-000049
- JSON: https://secwatch.observer/filing/0001689548-26-000049.json
- Plain text: https://secwatch.observer/filing/0001689548-26-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.